Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin

(2017) Shoko Ono et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

(2016) Hiroshi Matsumoto et al.   DIGESTIVE DISEASES AND SCIENCES

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis

(2016) Yi-Chia Lee et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Letter: promising results ofHelicobacter pylorieradication with vonoprazan-based triple therapy after failure of proton pump inhibitor-based triple therapy

(2015) T. Inaba et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Review article: the global emergence ofHelicobacter pyloriantibiotic resistance

(2015) I. Thung et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Seven-day triple therapy is a better choice forHelicobacter pylorieradication in regions with low antibiotic resistance

(2015) Yue-Feng Tong   WORLD JOURNAL OF GASTROENTEROLOGY

The fight against gastric cancer – the IARC Working Group report

(2014) Rolando Herrero et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Comparative study of esomeprazole and lansoprazole in triple therapy for eradication ofHelicobacter pyloriin Japan

(2014) Tsutomu Nishida   WORLD JOURNAL OF GASTROENTEROLOGY

An Easily Accessible Web-Based Minimization Random Allocation System for Clinical Trials

(2013) Lan Xiao et al.   JOURNAL OF MEDICAL INTERNET RESEARCH

Helicobacter pyloriresistance to antibiotics in Europe and its relationship to antibiotic consumption

(2012) Francis Megraud et al.   GUT

Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2012) Jyh-Ming Liou et al.   LANCET

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH

(2008) Julia Kirchheiner et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Tailored eradication therapy based on fecalHelicobacter pyloriclarithromycin sensitivities

(2008) Takashi Kawai et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY